Literature DB >> 1424277

The significance of serum soluble IL-2 receptor as a marker for active visceral leishmaniasis in Sicilian patients.

G Vitale1, G Reina, S Mansueto, R Malta, G Gambino, C Mocciaro, R D'Agostino, M Dieli, E Cillari.   

Abstract

Sera from nine Sicilian patients with confirmed visceral leishmaniasis (Leishmania donovani infantum; VL), at the moment of the diagnosis, during the course of the disease and after clinical recovery, were analysed for the concentration of soluble IL-2 receptor (sIL-2R). The results show that sIL-2R is a marker of disease activity, since it is in high concentration at the beginning of infection and returns to the normal range following successful chemotherapy. At the same time of serum analysis for sIL-2R, peripheral blood mononuclear cells (PBMC) of VL patients were stimulated with phytohaemagglutinin (PHA) or antigen and supernatant tested for IL-2 and interferon-gamma (IFN-gamma) production. Data demonstrate that there is an inverse relation between concentration of IL-2 and IFN-gamma in the supernatants and sIL-2R secretion in the sera.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424277      PMCID: PMC1554630          DOI: 10.1111/j.1365-2249.1992.tb07932.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Reduction in the number of UCHL-1+ cells and IL-2 production in the peripheral blood of patients with visceral leishmaniasis.

Authors:  E Cillari; S Milano; M Dieli; E Maltese; S Di Rosa; S Mansueto; A Salerno; F Y Liew
Journal:  J Immunol       Date:  1991-02-01       Impact factor: 5.422

2.  Immunological features of kala-azar.

Authors:  H R Rezai; S M Ardehali; G Amirhakimi; A Kharazmi
Journal:  Am J Trop Med Hyg       Date:  1978-11       Impact factor: 2.345

3.  Visceral leishmaniasis in Kenyan children.

Authors:  G M Anabwani; A D Bryceson
Journal:  Indian Pediatr       Date:  1982-10       Impact factor: 1.411

4.  Circulating factor from a kala-azar patient suppresses in vitro antileishmanial T cell proliferation.

Authors:  D J Wyler
Journal:  Trans R Soc Trop Med Hyg       Date:  1982       Impact factor: 2.184

5.  Counterimmunoelectrophoresis (CIEP) and ELISA tests in the diagnosis of canine leishmaniasis.

Authors:  S Mansueto; M D Miceli; P Quartararo
Journal:  Ann Trop Med Parasitol       Date:  1982-04

6.  Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis.

Authors:  J P Haldar; S Ghose; K C Saha; A C Ghose
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

7.  Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection.

Authors:  E M Carvalho; R S Teixeira; W D Johnson
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

8.  Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis.

Authors:  M Barral-Netto; A Barral; S B Santos; E M Carvalho; R Badaro; H Rocha; S G Reed; W D Johnson
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

9.  Immunosuppression in Kenyan visceral leishmaniasis.

Authors:  M Ho; D K Koech; D W Iha; A D Bryceson
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

10.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

View more
  10 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Early IL-2/sIL-2R surge following surgery leads to temporary immune refractoriness.

Authors:  N Lahat; R Shtiller; A Y Zlotnick; G Merin
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

3.  High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis.

Authors:  S Gasim; A M Elhassan; E A Khalil; A Ismail; A M Kadaru; A Kharazmi; T G Theander
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

4.  IL-15 in human visceral leishmaniasis caused by Leishmania infantum.

Authors:  S Milano; G Di Bella; P D'Agostino; C Barbera; R Caruso; M La Rosa; V Ferlazzo; G Vitale; C La Russa; G Gambino; N Chifari; S Mansueto; E Cillari
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

Review 5.  Whole blood assay and visceral leishmaniasis: Challenges and promises.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Immunobiology       Date:  2014-01-31       Impact factor: 3.144

6.  Evaluation of serum levels of soluble CD4, CD8 and beta 2-microglobulin in visceral human leishmaniasis.

Authors:  G Vitale; C Mocciaro; R Malta; G Gambino; A Spinelli; C Giordano; G Stassi; F Arcoleo; S Milano; E Cillari
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

7.  Serum soluble markers in the evaluation of treatment in human visceral leishmaniasis.

Authors:  A Schriefer; A Barral; E M Carvalho; M Barral-Netto
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

Review 8.  Post kala-azar dermal leishmaniasis: A threat to elimination program.

Authors:  Mallikarjuna Rao Gedda; Bhawana Singh; Dhiraj Kumar; Abhishek Kumar Singh; Prasoon Madhukar; Shreya Upadhyay; Om Prakash Singh; Shyam Sundar
Journal:  PLoS Negl Trop Dis       Date:  2020-07-02

9.  Biological significance of soluble IL-2 receptor.

Authors:  C Caruso; G Candore; D Cigna; A T Colucci; M A Modica
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711

10.  Visceral leishmaniasis in a patient with diabetes mellitus type 2 and discrete bicytopenia.

Authors:  Verena Schwetz; Christian Trummer; Claudia Friedl; Christine Beham-Schmid; Roman Kulnik; Albert Wölfler; Karl Horvath; Stefanie Wunsch; Jürgen Prattes; Ines Zollner-Schwetz; Thomas R Pieber; Julia K Mader; Robert Krause
Journal:  Clin Case Rep       Date:  2017-11-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.